Associations Between Single Nucleotide Polymorphisms of Hypoxia-Related Genes and Capsule Formation in Hepatocellular Carcinoma

References

• El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–2576. doi:10.1053/j.gastro.2007.04.061
   PubMed Web of Science ®Google Scholar
• Dasgupta P, Henshaw C, Youlden DR, Clark PJ, Aitken JF, Baade PD. Global trends in incidence rates of primary adult liver cancers: a systematic review and meta-analysis. Front Oncol. 2020;10:171. doi:10.3389/fonc.2020.00171
   PubMed Web of Science ®Google Scholar
• Llovet JM, De Baere T, Kulik L, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(5):293–313. doi:10.1038/s41575-020-00395-0
   PubMed Web of Science ®Google Scholar
• Di Federico A, Rizzo A, Carloni R, et al. Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials. Expert Opin Investig Drugs. 2022;31(4):361–369. doi:10.1080/13543784.2022.2009455
   PubMed Web of Science ®Google Scholar
• Damaskos C, Garmpis N, Dimitroulis D, et al. Targeted therapies for hepatocellular carcinoma treatment: a new era ahead-a systematic review. Int J Mol Sci. 2022;23(22):14117. doi:10.3390/ijms232214117
   PubMed Web of Science ®Google Scholar
• Oura K, Morishita A, Tani J, Masaki T. Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: a review. Int J Mol Sci. 2021;22(11):5801. doi:10.3390/ijms22115801
   PubMed Web of Science ®Google Scholar
• Liu M, Jiang L, Guan XY. The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update. Protein Cell. 2014;5(9):673–691. doi:10.1007/s13238-014-0065-9
   PubMed Web of Science ®Google Scholar
• Budhu A, Forgues M, Ye QH, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006;10(2):99–111. doi:10.1016/j.ccr.2006.06.016
   PubMed Web of Science ®Google Scholar
• Ishizaki M, Ashida K, Higashi T, et al. The formation of capsule and septum in human hepatocellular carcinoma. Virchows Arch. 2001;438(6):574–580. doi:10.1007/s004280000391
   PubMed Web of Science ®Google Scholar
• Torimura T, Ueno T, Inuzuka S, Tanaka M, Abe H, Tanikawa K. Mechanism of fibrous capsule formation surrounding hepatocellular carcinoma. Immunohistochemical study. Arch Pathol Lab Med. 1991;115(4):365–371.
   PubMed Web of Science ®Google Scholar
• Fu S, Wei J, Zhang J, et al. Selection between liver resection versus transarterial chemoembolization in hepatocellular carcinoma: a multicenter study. Clin Transl Gastroenterol. 2019;10(8):e00070. doi:10.14309/ctg.0000000000000070
   PubMedGoogle Scholar
• Ng IO, Lai EC, Ng MM, Fan ST. Tumor encapsulation in hepatocellular carcinoma. A pathologic study of 189 cases. Cancer. 1992;70(1):45–49. doi:10.1002/1097-0142(19920701)70:1<45::AID-CNCR2820700108>3.0.CO;2-7
   PubMed Web of Science ®Google Scholar
• Sun W, Zhang Y, Liu B, Duan Y, Li W, Chen J. Gene polymorphism of MUC15, MMP14, BRAF, and COL1A1 Is associated with capsule formation in hepatocellular carcinoma. Can J Gastroenterol Hepatol. 2021;2021:9990305. doi:10.1155/2021/9990305
   PubMed Web of Science ®Google Scholar
• Barry AE, Baldeosingh R, Lamm R, et al. Hepatic stellate cells and hepatocarcinogenesis. Front Cell Dev Biol. 2020;8:709. doi:10.3389/fcell.2020.00709
   PubMed Web of Science ®Google Scholar
• Roife D, Fleming JB, Gomer RH. Fibrocytes in the tumor microenvironment. Adv Exp Med Biol. 2020;1224:79–85.
   PubMed Web of Science ®Google Scholar
• Tse AP, Sze KM, Shea QT, et al. Hepatitis transactivator protein X promotes extracellular matrix modification through HIF/LOX pathway in liver cancer. Oncogenesis. 2018;7(5):44. doi:10.1038/s41389-018-0052-8
   PubMedGoogle Scholar
• Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer. 2014;14(6):430–439. doi:10.1038/nrc3726
   PubMed Web of Science ®Google Scholar
• Chen S, Morine Y, Tokuda K, et al. Cancer‑associated fibroblast‑induced M2‑polarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor‑1 pathway. Int J Oncol. 2021;59:2. doi:10.3892/ijo.2021.5239
   Web of Science ®Google Scholar
• De Ridder M, Jiang H, Van Esch G, et al. IFN-gamma+ CD8+ T lymphocytes: possible link between immune and radiation responses in tumor-relevant hypoxia. Int J Radiat Oncol Biol Phys. 2008;71(3):647–651. doi:10.1016/j.ijrobp.2008.03.014
   PubMed Web of Science ®Google Scholar
• Li W, Huang X, Tong H, et al. Comparison of the regulation of β-catenin signaling by type I, type II and type III interferons in hepatocellular carcinoma cells. PLoS One. 2012;7(10):e47040. doi:10.1371/journal.pone.0047040
   PubMed Web of Science ®Google Scholar
• Ohashi K, Yoshimoto T, Kosaka H, et al. Interferon γ and plasminogen activator inhibitor 1 regulate adhesion formation after partial hepatectomy. Br J Surg. 2014;101(4):398–407. doi:10.1002/bjs.9405
   PubMed Web of Science ®Google Scholar
• Kosaka H, Yoshimoto T, Yoshimoto T, Fujimoto J, Nakanishi K. Interferon-gamma is a therapeutic target molecule for prevention of postoperative adhesion formation. Nat Med. 2008;14(4):437–441. doi:10.1038/nm1733
   PubMed Web of Science ®Google Scholar
• Yoshimura A. Signal transduction of inflammatory cytokines and tumor development. Cancer Sci. 2006;97(6):439–447. doi:10.1111/j.1349-7006.2006.00197.x
   PubMed Web of Science ®Google Scholar
• Verras M, Papandreou I, Lim AL, Denko NC. Tumor hypoxia blocks Wnt processing and secretion through the induction of endoplasmic reticulum stress. Mol Cell Biol. 2008;28(23):7212–7224. doi:10.1128/MCB.00947-08
   PubMed Web of Science ®Google Scholar
• Monga SP. β-catenin signaling and roles in liver homeostasis, injury, and tumorigenesis. Gastroenterology. 2015;148(7):1294–1310. doi:10.1053/j.gastro.2015.02.056
   PubMed Web of Science ®Google Scholar
• Miao CG, Yang YY, He X, et al. Wnt signaling in liver fibrosis: progress, challenges and potential directions. Biochimie. 2013;95(12):2326–2335. doi:10.1016/j.biochi.2013.09.003
   PubMed Web of Science ®Google Scholar
• Zhang JZ, Behrooz A, Ismail-Beigi F. Regulation of glucose transport by hypoxia. Am J Kidney Dis. 1999;34(1):189–202. doi:10.1016/S0272-6386(99)70131-9
   PubMed Web of Science ®Google Scholar
• Ito S, Fukusato T, Nemoto T, Sekihara H, Seyama Y, Kubota S. Coexpression of glucose transporter 1 and matrix metalloproteinase-2 in human cancers. J Natl Cancer Inst. 2002;94(14):1080–1091. doi:10.1093/jnci/94.14.1080
   PubMedGoogle Scholar
• Ito H, Duxbury M, Zinner MJ, Ashley SW, Whang EE. Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity. Surgery. 2004;136(3):548–556. doi:10.1016/j.surg.2004.05.032
   PubMed Web of Science ®Google Scholar
• Chao JS, Zhu Q, Chen DS, et al. Combined analysis of imaging tumor capsule with imaging tumor size guides the width of resection margin for solitary hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2022;21(6):551–558. doi:10.1016/j.hbpd.2021.12.009
   PubMed Web of Science ®Google Scholar
• Chen S, Peng Z, Zhang Y, et al. Lack of response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: abandon or repeat? Radiology. 2021;298(3):680–692. doi:10.1148/radiol.2021202289
   PubMed Web of Science ®Google Scholar
• Wu LF, Xu GP, Zhao Q, Zhou LJ, Wang D, Chen WX. The association between hypoxia inducible factor 1 subunit alpha gene rs2057482 polymorphism and cancer risk: a meta-analysis. BMC Cancer. 2019;19(1):1123. doi:10.1186/s12885-019-6329-2
   PubMed Web of Science ®Google Scholar
• Li HN, He T, Zha YJ, et al. HIF-1α rs11549465 C>T polymorphism contributes to increased cancer susceptibility: evidence from 49 studies. J Cancer. 2019;10(24):5955–5963. doi:10.7150/jca.35716
   PubMed Web of Science ®Google Scholar
• Guo X, Li D, Chen Y, et al. SNP rs2057482 in HIF1A gene predicts clinical outcome of aggressive hepatocellular carcinoma patients after surgery. Sci Rep. 2015;5:11846. doi:10.1038/srep11846
   PubMed Web of Science ®Google Scholar
• Liu H, Wang Z, Yu S, Xu J. Proteasomal degradation of O-GlcNAc transferase elevates hypoxia-induced vascular endothelial inflammatory response†. Cardiovasc Res. 2014;103(1):131–139. doi:10.1093/cvr/cvu116
   PubMed Web of Science ®Google Scholar
• Liu XS, Gao Y, Wu LB, et al. Comprehensive analysis of GLUT1 immune infiltrates and ceRNA network in human esophageal carcinoma. Front Oncol. 2021;11:665388. doi:10.3389/fonc.2021.665388
   PubMedGoogle Scholar
• Ancey PB, Contat C, Meylan E. Glucose transporters in cancer - from tumor cells to the tumor microenvironment. Febs j. 2018;285(16):2926–2943. doi:10.1111/febs.14577
   PubMed Web of Science ®Google Scholar
• Sun HW, Yu XJ, Wu WC, et al. GLUT1 and ASCT2 as predictors for prognosis of hepatocellular carcinoma. PLoS One. 2016;11(12):e0168907. doi:10.1371/journal.pone.0168907
   PubMed Web of Science ®Google Scholar
• Zhou H, Wang L, Li X, et al. Interferon-γ +874A/T polymorphism and hepatocellular carcinoma risk: a meta-analysis. Med Sci Monit. 2015;21:689–693. doi:10.12659/MSM.892885
   PubMed Web of Science ®Google Scholar
• Kim HJ, Chung JH, Shin HP, et al. Polymorphisms of interferon gamma gene and risk of hepatocellular carcinoma in Korean patients with chronic hepatitis B viral infection. Hepato-gastroenterology. 2013;60(125):1117–1120. doi:10.5754/hge11333
   PubMedGoogle Scholar
• He X, Sun Y, Lei N, et al. MicroRNA-351 promotes schistosomiasis-induced hepatic fibrosis by targeting the vitamin D receptor. Proc Natl Acad Sci U S A. 2018;115(1):180–185. doi:10.1073/pnas.1715965115
   PubMed Web of Science ®Google Scholar
• Attallah AM, El-Far M, Zahran F, et al. Interferon-gamma is associated with hepatic dysfunction in fibrosis, cirrhosis, and hepatocellular carcinoma. J Immunoassay Immunochem. 2016;37(6):597–610. doi:10.1080/15321819.2016.1179646
   PubMedGoogle Scholar
• Yamashita N, Long M, Fushimi A, et al. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer. J Immunother Cancer. 2021;9:1. doi:10.1136/jitc-2020-002115
   Web of Science ®Google Scholar
• Saxena R, Chawla YK, Verma I, Kaur JIFN. γ (+874) and not TNF-α (−308) is associated with HBV-HCC risk in India. Mol Cell Biochem. 2014;385(1–2):297–307. doi:10.1007/s11010-013-1838-9
   PubMed Web of Science ®Google Scholar
• Zhu ZZ, Di JZ, Gu WY, et al. Association of genetic polymorphisms in STAT1 gene with increased risk of hepatocellular carcinoma. Oncology. 2010;78(5–6):382–388. doi:10.1159/000320521
   PubMed Web of Science ®Google Scholar
• Cong WM, Wu MC. The biopathologic characteristics of DNA content of hepatocellular carcinomas. Cancer. 1990;66(3):498–501. doi:10.1002/1097-0142(19900801)66:3<498::AID-CNCR2820660316>3.0.CO;2-2
   PubMed Web of Science ®Google Scholar
• Wakasa K, Sakurai M, Okamura J, Kuroda C. Pathological study of small hepatocellular carcinoma: frequency of their invasion. Virchows Arch a Pathol Anat Histopathol. 1985;407(3):259–270. doi:10.1007/BF00710651
   PubMedGoogle Scholar
• Li W, Tong H, Huang X, Wang W, Wu H, Lin S. High levels of β-catenin promote IFNγ-induced apoptosis in hepatocellular carcinoma cells. Oncol Lett. 2012;4(5):1092–1096. doi:10.3892/ol.2012.844
   PubMed Web of Science ®Google Scholar
• Bai M, Li W, Yu N, Zhang H, Long F, Zeng A. The crosstalk between β-catenin signaling and type I, type II and type III interferons in lung cancer cells. Am J Transl Res. 2017;9(6):2788–2797.
   PubMed Web of Science ®Google Scholar
• Li QM, Zhang FQ, Li YF, Xian QJ, Zhang YQ, Li P. Influence of polymorphisms in the Wnt/β-catenin pathway genes on hepatocellular carcinoma risk in a Chinese Han population. Medicine. 2017;96(12):e6127. doi:10.1097/MD.0000000000006127
   PubMed Web of Science ®Google Scholar
• Jing X, Yang F, Shao C, et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019;18(1):157. doi:10.1186/s12943-019-1089-9
   PubMed Web of Science ®Google Scholar
• Luoto KR, Kumareswaran R, Bristow RG. Tumor hypoxia as a driving force in genetic instability. Genome Integr. 2013;4(1):5. doi:10.1186/2041-9414-4-5
   PubMedGoogle Scholar
• Chu KK, Chan SC, Fan ST, et al. Radiological prognosticators of hepatocellular carcinoma treated by hepatectomy. Hepatobiliary Pancreat Dis Int. 2012;11(6):612–617. doi:10.1016/S1499-3872(12)60232-X
   PubMed Web of Science ®Google Scholar
• Adachi E, Maeda T, Kajiyama K, et al. Factors correlated with portal venous invasion by hepatocellular carcinoma: univariate and multivariate analyses of 232 resected cases without preoperative treatments. Cancer. 1996;77(10):2022–2031. doi:10.1002/(SICI)1097-0142(19960515)77:10<2022::AID-CNCR9>3.0.CO;2-S
   PubMed Web of Science ®Google Scholar
• Siriwardana PN, Luong TV, Watkins J, et al. Biological and prognostic significance of the morphological types and vascular patterns in colorectal liver metastases (CRLM): looking beyond the tumor margin. Medicine. 2016;95(8):e2924. doi:10.1097/MD.0000000000002924
   PubMed Web of Science ®Google Scholar